|
| Age (years, range) | |
| Mean | 59.06 (33–80) |
| Gender (, %) | |
| Male | 19 (54.29%) |
| Female | 14 (40.00%) |
| NA | 2 (5.71%) |
| Diagnosis of cancers (, %) | |
| Metastatic renal cell cancer | 10 (28.57%) |
| Metastatic colorectal cancer | 6 (17.14%) |
| Metastatic breast cancer | 5 (14.29%) |
| Other cancers | 14 (40.00%) |
| Metastatic non-small-cell lung cancer | 4 |
| Glioblastoma multiforme | 2 |
| Medullary thyroid cancer | 2 |
| Malignant parotid tumour | 1 |
| Pancreatic cancer | 1 |
| Metastatic hepatocellular carcinoma | 1 |
| Metastatic carcinoid cancer | 1 |
| Metastatic oesophageal cancer | 1 |
| Presenting complaints (, %) | |
| Jaw pain | 12 (34.29%) |
| Jaw pain with other complaints | 6 (17.14%) |
| Asymptomatic | 8 (22.86%) |
| Jaw discomfort | 1 (2.86%) |
| Spontaneous teeth loss | 1 (2.86%) |
| Limited mouth opening and submandibular area swelling | 1 (2.86%) |
| Gingival bleeding | 1 (2.86%) |
| NA | 5 (14.29%) |
| Clinical presentation (, %) | |
| Bone exposure MRONJ | 32 (91.43%) |
| Nonexposed MRONJ | 3 (8.57%) |
| Location | |
| Mandible | 29 (82.86%) |
| Maxilla | 4 (11.43%) |
| NA | 2 (6.67%) |
| Types of antiangiogenic agents (, %) | |
| Bevacizumab | 14 (40%) |
| Aflibercept | 5 (14.29%) |
| Sunitinib | 3 (8.57%) |
| Cabozantinib | 2 (5.71%) |
| Sorafenib | 1 (2.86%) |
| Temsirolimus | 1 (2.86%) |
| Everolimus | 1 (2.86%) |
| Dasatinib | 1 (2.86%) |
| Multiple antiangiogenic agents | 7 (20.00%) |
| Route of antiangiogenic administrations (, %) | |
| Intravenous administration | 21 (60.00%) |
| Oral administration | 12 (34.29%) |
| Combination of intravenous administration and oral administration | 2 (5.71%) |
| Time to MRONJ (months, 95% CI) | |
| Intravenous antiangiogenics | 6.49 (2.67–10.30) |
| Oral antiangiogenics | 16.72 (2.59–30.84) |
| Predisposing factors (, %) | |
| Extraction | 13 (37.14%) |
| Periodontal disease | 3 (8.57%) |
| Minor trauma from use of denture | 4 (11.43%) |
| Dental implant | 1 (2.86%) |
| Mean time to MRONJ after extraction (months, 95% CI) | 3.09 (0.40–5.77) |
| Management of MRONJ (, %) | |
| Surgical treatment | 17 (48.57%) |
| Minimally invasive surgical procedures | 11 |
| Major surgical procedures | 6 |
| Nonsurgical treatment | 16 (45.71%) |
| No treatment | 1 (2.86%) |
| NA | 1 (2.86%) |
| Treatment outcomes (, %) | |
| Disease resolution | 18 (62.06%) |
| Mean time to resolution (months, 95% CI) | 6.75 (0.90–12.59) |
| Incomplete resolution | 11 (37.93%) |
| NA | 6 |
|
